Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO, and Krissy Wright...
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cardiol Therapeutics (CRDL Research Report), Paragon 28...
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Paragon 28 (FNA Research Report) and Caribou Biosciences...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Latest Ratings for FNA
DateFirmActionFromTo Mar 2022B of A SecuritiesMaintainsBuy Mar 2022Canaccord GenuityMaintainsBuy Feb 2022NeedhamMaintainsBuy
View More Analyst Ratings for FNA...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
OXFORD, United Kingdom, April 04, 2024 (GLOBE NEWSWIRE) -- OrganOx, a medical device company which is changing the paradigm in liver transplantation in the US and Europe with its groundbreaking...
Needham Company LLC reissued their buy rating on shares of Paragon 28 (NYSE:FNA - Free Report) in a research note published on Thursday, Benzinga reports. Needham Company LLC currently...
Paragon 28 (NYSE:FNA Get Free Report)s stock had its overweight rating reissued by analysts at Piper Sandler in a report issued on Wednesday, Benzinga reports. They...